Drug Trial News

RSS

First patient dosed in second Phase 2 study with LiRIS for treatment of Interstitial Cystitis

TARIS Biomedical, a specialty pharmaceutical company developing innovative, targeted therapies to treat bladder diseases with high unmet medical need, announced today that it has dosed the first patient in its second Phase 2 clinical study with LiRIS, its novel product candidate, in patients with Interstitial Cystitis.

3 Apr 2013

Researchers to test cyclodextrin for treating Niemann-Pick Type C disease

Washington University School of Medicine in St. Louis is playing a leading role in one of the National Institutes of Health's (NIH) first clinical trials to improve treatments for rare and neglected diseases.

3 Apr 2013

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer.

2 Apr 2013

N30 Pharmaceuticals presents preclinical data of GSNORi at European Cystic Fibrosis Society meeting

N30 Pharmaceuticals, Inc., a clinical stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis, announced today the presentation of key preclinical data for its novel inhibitors of S-nitrosoglutathione reductase.

2 Apr 2013

Inovio Pharmaceuticals reports release of phase II clinical trial results of ChronVac-C

Inovio Pharmaceuticals, Inc. today announced the release of preliminary clinical trial results by its collaborator ChronTech AS of their open label phase II clinical study of ChronVac-C, ChronTech's vaccine to treat hepatitis C virus infection.

2 Apr 2013

Phase II study shows effectiveness of Axelar's AXL-003 in treating patients with NSCLC

Axelar AB, part of the Karolinska Development AB portfolio, announced today that preliminary interim results of its Phase II study AXL-003, indicates that AXL1717 is effective in treating patients with non-small cell lung cancer.

2 Apr 2013

Ampio Pharmaceuticals receives FDA IND approval to start clinical trial of Ampion

Ampio Pharmaceuticals, Inc. today announced FDA acceptance of its IND and the treatment of the first fifteen (15) patients in its clinical trial using Ampion™ to treat osteoarthritis of the knee.

2 Apr 2013

Ensemble Therapeutics to highlight IL-17A inhibitor Ensemblin at 245th ACS National Meeting

Ensemble Therapeutics today announced that preclinical data showing the advantages of its Ensemblins, novel macrocyclic compounds against challenging drug targets, will be presented at the 245th American Chemical Society National Meeting being held April 7-11, 2013 in New Orleans, LA.

2 Apr 2013

Adenosine Therapeutics to explore strategic options for Stedivaze

Adenosine Therapeutics, LLC, a drug discovery and development company founded in 1999, announced today that it has engaged Needham & Company to explore strategic options for Stedivaze, a highly selective adenosine A2A agonist being developed as a pharmacological stress agent for use in Myocardial Perfusion Imaging.

2 Apr 2013

Phase 2 study of REOLYSIN meets primary endpoint in patients with squamous cell lung cancer

Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy naïve for their metastatic or recurrent cancer (REO 021).

28 Mar 2013

Neurological researchers study promising new treatment for deadly brain tumors

A promising new treatment for deadly brain tumors taken orally with minimal side effects is being studied by neurological researchers at Rush University Medical Center, Chicago.

28 Mar 2013

CureVac begins CV9104 Phase 2b clinical trial in patients with castration-resistant prostate cancer

CureVac GmbH, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA, today announced that it has initiated a double-blind, randomized Phase 2b clinical trial of its RNActive cancer vaccine, CV9104, for the treatment of patients with castration-resistant prostate cancer.

28 Mar 2013

Virginia G. Piper Cancer Center Clinical Trials successfully tests cabozantinib

The FDA has approved a thyroid cancer drug successfully tested at Virginia G. Piper Cancer Center Clinical Trials, a partnership of Scottsdale Healthcare and the Translational Genomics Research Institute.

28 Mar 2013

Neurocrine Biosciences starts elagolix Phase IIb clinical trial for treatment of uterine fibroids

Neurocrine Biosciences, Inc. today announced that a Phase IIb clinical trial to evaluate elagolix for the treatment of uterine fibroids has been initiated.

27 Mar 2013

FDA clears Soligenix's IND application for SGX942 for treatment of oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company, announced today that the Food and Drug Administration has completed its review and cleared the Investigational New Drug application for SGX942 for the treatment of oral mucositis resulting from radiation and/or chemotherapy treatment in head and neck cancer patients.

27 Mar 2013

Lightlake to present Phase II clinical trial results of opioid antagonist nasal spray at APA Annual Meeting

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Company's Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder has been accepted for presentation at the American Psychiatric Association Annual Meeting taking place in San Francisco, California, May 18-22, 2013.

27 Mar 2013

Ketamine may help treat severe depression, reduce suicidal urges, UAB researchers say

University of Alabama at Birmingham researchers think ketamine, an anesthesia medication in use since the 1970s, might be a valuable tool in treating severe depression and reducing suicidal urges; they have launched two studies to explore the possibility.

27 Mar 2013

Study shows benefit of azithromycin in patients with non-CF bronchiectasis

Among patients with the lung disorder non-cystic fibrosis bronchiectasis, treatment with the antibiotic azithromycin resulted in improvement in symptoms but also increased the risk of antibiotic resistance, according to a study appearing in the March 27 issue of JAMA.

27 Mar 2013

Erythromycin may provide benefit for patients with non-CF bronchiectasis

Among patients with the lung disorder non-cystic fibrosis bronchiectasis, treatment with the antibiotic erythromycin resulted in improvement in symptoms but also increased the risk of antibiotic resistance, according to a study appearing in the March 27 issue of JAMA.

27 Mar 2013

Auxilium Pharmaceuticals reports positive results from phase IIa Frozen Shoulder Syndrome clinical trial

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive data for collagenase clostridium histolyticum or CCH which is being developed for the potential treatment, if approved by the U.S. Food and Drug Administration, of adult patients with adhesive capsulitis, commonly known as Frozen Shoulder syndrome.

26 Mar 2013

Drug Trial News

First patient dosed in second Phase 2 study with LiRIS for treatment of Interstitial Cystitis

Researchers to test cyclodextrin for treating Niemann-Pick Type C disease

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

N30 Pharmaceuticals presents preclinical data of GSNORi at European Cystic Fibrosis Society meeting

Inovio Pharmaceuticals reports release of phase II clinical trial results of ChronVac-C

Phase II study shows effectiveness of Axelar's AXL-003 in treating patients with NSCLC

Ampio Pharmaceuticals receives FDA IND approval to start clinical trial of Ampion

Ensemble Therapeutics to highlight IL-17A inhibitor Ensemblin at 245th ACS National Meeting

Adenosine Therapeutics to explore strategic options for Stedivaze

Phase 2 study of REOLYSIN meets primary endpoint in patients with squamous cell lung cancer

Neurological researchers study promising new treatment for deadly brain tumors

CureVac begins CV9104 Phase 2b clinical trial in patients with castration-resistant prostate cancer

Virginia G. Piper Cancer Center Clinical Trials successfully tests cabozantinib

Neurocrine Biosciences starts elagolix Phase IIb clinical trial for treatment of uterine fibroids

FDA clears Soligenix's IND application for SGX942 for treatment of oral mucositis

Lightlake to present Phase II clinical trial results of opioid antagonist nasal spray at APA Annual Meeting

Ketamine may help treat severe depression, reduce suicidal urges, UAB researchers say

Study shows benefit of azithromycin in patients with non-CF bronchiectasis

Erythromycin may provide benefit for patients with non-CF bronchiectasis

Auxilium Pharmaceuticals reports positive results from phase IIa Frozen Shoulder Syndrome clinical trial

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest News